ArticleBMC pediatrics2025
The application of pre-discharge delta total bilirubin to predict the need for post-discharge phototherapy in healthy neonates 35 weeks' gestation or later.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe American Academy of Pediatrics recommended the use of pre-discharge delta total bilirubin (DeltaTB) to determine appropriate follow-up timing.
objectivesTo determine the proportion of neonates requiring post-discharge phototherapy after applying the pre-discharge DeltaTB approach, and to assess its effectiveness in predicting phototherapy needs.
methodsThis is a prospective cohort study conducted at Chiang Mai University Hospital. The pre-discharge DeltaTB, defined as the difference between the bilirubin level and the phototherapy threshold at the time of measurement. Based on pre-discharge DeltaTB (mg/dL), patients were categorized into 3 risk groups: high-risk (< 3.5), moderate risk (3.5–6.9) and low risk (> 7). Post-discharge phototherapy, pre-discharge TB, and number of follow-up were compared between the risk groups. DeltaTB levels in different age intervals were analyzed using ROC curve analysis to determine the cutoff in each interval.
resultsOut of 150 neonates, 31 (20.6%) required post-discharge phototherapy, with 9 (6.0%) neonates were classified as requiring subthreshold phototherapy. There were 17.3%, 53.3% and 19.3% of 150 neonates categorized as high, moderate, and low risk by pre-discharge DeltaTB, respectively. The high-risk group, had the highest proportion of post-discharge phototherapy, mean pre-discharge bilirubin level and number of follow-up visits and were significantly different from other groups (P-value < 0.001). The optimal timing for measuring pre-discharge bilirubin was aged 49–72 h (AUC of 0.851).
conclusionPre-discharge DeltaTB effectively stratified neonates by risk for post-discharge phototherapy and may guide timely follow-up to prevent severe hyperbilirubinemia, with significantly higher rates in the high-risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.